Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prognostic Factors for All Types of Cancer Combined (ProFaCo)

This study has been completed.
Sponsor:
Collaborator:
Maastricht University Medical Center
Information provided by (Responsible Party):
Dennis Japink, Atrium Medical Center
ClinicalTrials.gov Identifier:
NCT00704587
First received: June 23, 2008
Last updated: April 5, 2016
Last verified: April 2016
  Purpose
The purpose of this study is to investigate every possible applicability of flow cytometrical analysis in the intracellular detection of tumor-related material in activated macrophages in the broadest range of cancer types.

Condition
Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Flow Cytometrical Analysis of the Human Immune System to Assess Tumor-related Material Piling up in Activated Macrophages in All Relevant Cancer Types.

Further study details as provided by Atrium Medical Center:

Primary Outcome Measures:
  • screening and followup [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

white cells

tissue

plasma

serum


Enrollment: 520
Study Start Date: November 2006
Study Completion Date: July 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
all patients diagnosed or suspected of cancerous conditions in the broadest sense of the word
Criteria

Inclusion Criteria:

  • (Suspicion of) presence of cancer in the broadest sense of the word
  • Must be able to understand and sign written informed consent

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00704587

Locations
Netherlands
Atrium Medical Centre Parkstad
Heerlen, Limburg, Netherlands, 6401 PC
Maastricht University Medical Centre
Maastricht, Limburg, Netherlands, 6202 AZ
Sponsors and Collaborators
Atrium Medical Center
Maastricht University Medical Center
Investigators
Principal Investigator: Dennis Japink, MD Atrium Medical Centre Parkstad, Heerlen
  More Information

Responsible Party: Dennis Japink, drs, Atrium Medical Center
ClinicalTrials.gov Identifier: NCT00704587     History of Changes
Other Study ID Numbers: ProFaCo  METC 06-p-47  MEC 08-02-030  NL14215.096.06 
Study First Received: June 23, 2008
Last Updated: April 5, 2016
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Atrium Medical Center:
cancer occurence
cancer recurrence
neo-adjuvant treatment response measurement

ClinicalTrials.gov processed this record on December 07, 2016